Patrick Alexander Ott
#158,947
Most Influential Person Now
Patrick Alexander Ott's AcademicInfluence.com Rankings
Patrick Alexander Ottphilosophy Degrees
Philosophy
#9086
World Rank
#12591
Historical Rank
Logic
#6080
World Rank
#7562
Historical Rank

Download Badge
Philosophy
Why Is Patrick Alexander Ott Influential?
(Suggest an Edit or Addition)Patrick Alexander Ott's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. (2015) (2383)
- An immunogenic personal neoantigen vaccine for patients with melanoma (2017) (1820)
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy (2018) (1272)
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. (2016) (975)
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018) (754)
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. (2016) (730)
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients (2013) (595)
- Towards personalized, tumour-specific, therapeutic vaccines for cancer (2017) (577)
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. (2016) (513)
- T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. (2019) (481)
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. (2016) (455)
- Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. (2013) (432)
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (2018) (381)
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy (2016) (381)
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial (2016) (376)
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. (2017) (368)
- Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. (2013) (346)
- Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma (2017) (345)
- PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course (2016) (341)
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (2017) (322)
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. (2017) (305)
- Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. (2018) (294)
- Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. (2017) (293)
- Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (289)
- Combination immunotherapy: a road map (2017) (287)
- Advances in the development of personalized neoantigen-based therapeutic cancer vaccines (2021) (273)
- Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies (2016) (272)
- A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer (2020) (231)
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study (2018) (227)
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (2018) (224)
- The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma (2016) (204)
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study (2014) (197)
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data (2015) (196)
- A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab (2015) (188)
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab (2015) (187)
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial (2016) (186)
- Clinical activity of ipilimumab for metastatic uveal melanoma (2013) (176)
- Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma (2021) (168)
- Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery (2013) (167)
- HLA-Binding Properties of Tumor Neoepitopes in Humans (2014) (165)
- Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. (2019) (165)
- Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. (2020) (146)
- 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028 (2015) (146)
- Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. (2015) (144)
- Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. (2016) (142)
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. (2019) (141)
- Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma (2021) (140)
- Ipilimumab for patients with advanced mucosal melanoma. (2013) (140)
- PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. (2018) (136)
- Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis (2017) (134)
- Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. (2017) (125)
- Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma (2013) (121)
- Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal (2017) (113)
- Vemurafenib and radiation therapy in melanoma brain metastases (2013) (111)
- A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates (2010) (104)
- Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal (2017) (102)
- Mucosal melanomas: a case-based review of the literature. (2010) (101)
- Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties (2013) (101)
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma (2015) (100)
- Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028 (2016) (99)
- Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. (2015) (99)
- Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy (2017) (95)
- Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions (2017) (95)
- The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. (2019) (91)
- Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition (2019) (90)
- CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). (2016) (88)
- Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. (2017) (87)
- Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study (2020) (85)
- Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. (2003) (83)
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. (2021) (79)
- NCCN Guidelines® insights: Melanoma, version 3.2016: Featured updates to the NCCN Guidelines (2016) (79)
- The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. (2020) (76)
- Talimogene Laherparepvec for the Treatment of Advanced Melanoma (2016) (73)
- Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma (2015) (72)
- Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. (2014) (72)
- Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. (2017) (71)
- Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. (2016) (70)
- Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node (2012) (65)
- Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management (2018) (64)
- PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. (2015) (63)
- A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. (2020) (57)
- T Cells Recognize Multiple GAD65 and Proinsulin Epitopes in Human Type 1 Diabetes, Suggesting Determinant Spreading (2004) (56)
- Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. (2011) (54)
- Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. (2016) (53)
- 427OPembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study (2017) (52)
- Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas (2015) (51)
- Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer. (2016) (51)
- Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. (2017) (50)
- Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study (2016) (49)
- A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. (2018) (47)
- CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. (2004) (47)
- Directing Traffic: How to Effectively Drive T Cells into Tumors. (2020) (47)
- NCCN Guidelines Insights: Melanoma, Version 3.2016. (2016) (45)
- Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 (2015) (45)
- Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes (2002) (45)
- Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. (2016) (44)
- Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. (2015) (43)
- Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. (2017) (43)
- Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies (2018) (42)
- A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma (2019) (42)
- The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice (2005) (42)
- Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial (2012) (42)
- Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. (2015) (38)
- Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma (2016) (37)
- Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma (2017) (36)
- Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients (2017) (36)
- Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function (2013) (35)
- Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer (2021) (33)
- IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. (2005) (33)
- New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy (2014) (32)
- Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. (2005) (32)
- Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies (2019) (30)
- The Biology and Clinical Development of MEK Inhibitors for Cancer (2014) (30)
- A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. (2014) (29)
- Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma (2019) (29)
- An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. (2019) (29)
- Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study. (2016) (28)
- CD4+CD25+ regulatory T cells control the progression from periinsulitis to destructive insulitis in murine autoimmune diabetes. (2005) (28)
- Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. (2019) (26)
- Increased in vivo frequency of IA-2 peptide-reactive IFNgamma+/IL-4- T cells in type 1 diabetic subjects. (2004) (26)
- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. (2020) (26)
- MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial (2017) (25)
- Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma (2018) (25)
- Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. (2014) (24)
- OA05.01 Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028 (2017) (24)
- Landscape of helper and regulatory antitumour CD4+ T cells in melanoma (2022) (23)
- Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). (2016) (23)
- Novel therapeutics for melanoma (2009) (23)
- Vaccines and melanoma. (2014) (23)
- Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis (2020) (23)
- A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer. (2018) (22)
- Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma (2017) (22)
- NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. (2020) (21)
- Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1 (2020) (21)
- Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial (2020) (20)
- Phase II Trial of Dacarbazine and Thalidomide for the Treatment of Metastatic Melanoma (2009) (20)
- Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma (2018) (20)
- Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors (2018) (20)
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series (2017) (20)
- Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma (2015) (19)
- Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. (2017) (19)
- Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study (2019) (19)
- Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. (2020) (18)
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study (2018) (18)
- 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 (2015) (18)
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series (2017) (18)
- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. (2022) (17)
- Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). (2016) (17)
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
- Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors (2021) (16)
- Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors (2020) (16)
- Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. (2017) (16)
- Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. (2019) (16)
- Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications. (1998) (16)
- PD-1 inhibitors in endometrial cancer (2017) (15)
- The secretory IFN-gamma response of single CD4 memory cells after activation on different antigen presenting cell types. (2007) (15)
- Hair depigmentation as an indicator of durable response to CTLA-4 therapy. (2010) (15)
- Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy (2020) (14)
- Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study. (2017) (14)
- A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). (2013) (14)
- Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples (2021) (14)
- Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic? (2013) (14)
- Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer (2019) (14)
- CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study (2021) (14)
- Cutaneous Melanoma , Version 2 . 2019 (2019) (13)
- T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types. (2016) (13)
- Cancer Immunotherapy Principles and Practice (2018) (13)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence (2015) (12)
- Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC) (2019) (12)
- Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL) (2016) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Surgical approach to primary cutaneous melanoma. (2011) (11)
- CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study (2021) (11)
- The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. (2012) (11)
- A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma (2010) (11)
- Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma (2019) (10)
- Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM). (2016) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Personal Neoantigen Vaccines for the Treatment of Cancer (2021) (9)
- Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1. (2016) (9)
- Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study. (2018) (9)
- Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge (2016) (9)
- Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma (2016) (9)
- A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. (2017) (8)
- Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders (2021) (8)
- Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes (2019) (8)
- H05Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 (2015) (7)
- 674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032 (2017) (7)
- A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma (2016) (7)
- Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine. (2018) (6)
- A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors. (2015) (6)
- Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation. (2016) (6)
- A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. (2015) (6)
- Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broadde novoanti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer (2018) (6)
- Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study. (2014) (6)
- Intralesional Cancer Immunotherapies. (2019) (6)
- Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM). (2016) (6)
- Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer. (2016) (6)
- Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy. (2015) (6)
- Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (2017) (6)
- Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care (2017) (6)
- 3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC) (2015) (6)
- 84PDRelationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) (2017) (6)
- Challenges in neoantigen-directed therapeutics. (2022) (5)
- Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. (2022) (5)
- Immunotherapy: Immune-modified response criteria — an iterative learning process? (2018) (5)
- First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors (2022) (5)
- Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy (2018) (5)
- Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients (2021) (5)
- Long-term Overall Survival and Predictors in Anti–PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study (2021) (4)
- Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis. (2020) (4)
- Genomic biomarkers in relation to PD-1 checkpoint blockade response. (2018) (4)
- General Principles of Immune-Related Toxicities (2019) (4)
- Treatment for advanced melanoma: new drugs, new opportunities, new challenges. (2013) (4)
- Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial (2021) (4)
- Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma (2012) (4)
- Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service (2020) (4)
- KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma. (2022) (4)
- Cancer vaccines (2022) (3)
- Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. (2021) (3)
- Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1 (2016) (3)
- Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. (2017) (3)
- Abstract 5631: Personal neoantigen-targeting vaccination generates neoepitope-specific T cell responses in tumors of patients with glioblastoma (2018) (3)
- Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study (2021) (3)
- Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors. (2018) (3)
- Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma. (2016) (3)
- Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era (2022) (3)
- A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). (2020) (3)
- Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD). (2020) (3)
- A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013 (2018) (2)
- Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238. (2021) (2)
- Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab (2017) (2)
- Immune-related tumor response dynamics in melanoma patients (pts) treated with pembrolizumab: Identifying markers for clinical outcome and treatment decisions. (2017) (2)
- Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. (2009) (2)
- Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma (2013) (2)
- A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). (2)
- Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials. (2018) (2)
- Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. (2012) (2)
- Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study (2016) (2)
- Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading (2019) (2)
- Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs). (2018) (2)
- [Immediate results of combined treatment for soft tissue sarcomas including intraoperative radiation therapy]. (2013) (2)
- Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade (2021) (2)
- 1142PDSafety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb (2017) (2)
- Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. (2017) (2)
- Use of Vemurafenib, a BRAF Inhibitor Along With Radiation Therapy in Melanoma Brain Metastasis (2012) (2)
- Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma. (2014) (2)
- PD-1 inhibition - trouble for subsequent TIL therapy in patients with melanoma? (2022) (2)
- 481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors (2020) (2)
- Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy (2019) (2)
- Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. (2022) (2)
- How physicians can help create useful clinical practice guidelines. (1999) (1)
- T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer (2015) (1)
- 1207TiPAn open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder (2017) (1)
- Abstract P6-18-31: PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072 (2019) (1)
- Abstract 4989: Toxicity profile of contemporaneous PD-1 inhibitor immunotherapy and radiotherapy (2016) (1)
- Detecting neoepitope-specific intra-tumoral T cell responses in a glioblastoma patient treated with personal neoantigen vaccine (2018) (1)
- Retrospective review of outcomes following radiotherapy for oligoprogressive disease on immune checkpoint blockade. (2022) (1)
- Principles of Combination Immunotherapies (2021) (1)
- Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy. (2021) (1)
- PD-1 and PD-L1 Inhibition in the Treatment of Advanced Melanoma (2014) (1)
- Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH). (2011) (1)
- T-cell receptory AV repertoire analysis of peripheral blood lymphocytes in antibody positive first degree relatives and type 1 diabetic patients (1996) (1)
- 655 Landscape of helper and regulatory CD4+ T cells in melanoma (2021) (1)
- PD-1 inhibitor-related pneumonitis in advanced cancer patients. (2016) (1)
- 648 Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors (2020) (1)
- Optimized liquid and gas phase fractionation increase HLA-peptidome coverage for primary cell and tissue samples (2021) (1)
- An open-label, phase Ib study of NEO-PV-01 + adjuvant with nivolumab in patients with melanoma, non-small cell lung carcinoma, or transitional cell carcinoma of the bladder. (2017) (1)
- Abstract CT166: A Phase I/II, open-label, two part study of GSK3359609 in combination with tremelimumab in participants with selected, advanced solid tumors (2019) (1)
- Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer (2019) (1)
- Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): Matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032. (2018) (1)
- Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma (2017) (1)
- Immune-related tumor response dynamics as a marker for survival and treatment benefit during PD-1 inhibitor therapy. (2016) (1)
- 511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors (2021) (1)
- Thromboembolism (TE) and association with survival in patients (pts) with melanoma receiving chemo– or immunotherapy. (2022) (1)
- Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) (2021) (0)
- Impact of Palliative Radiation on Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio in Patients Receiving PD-1 Inhibitors (2018) (0)
- The part of direct angiography as specification for an excision of giant recurrent tumor of retroperitoneal space (2013) (0)
- Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma (2020) (0)
- Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma (2017) (0)
- Cell metastasis in Melanoma (2012) (0)
- Immunotherapy: An Old and New Modality for the Treatment of Cancer. (2019) (0)
- Clinical experience and correlates of ipilimumab 3 mg/kg with GM-CSF in advanced melanoma. (2015) (0)
- Neoantigen-directed therapeutics in the clinic: where are we? (2023) (0)
- A novel framework for evaluating biomarker response relationships in immuno-oncology (IO). (2018) (0)
- Ipilimumab in Melanoma With Limited Brain Metastasis Treated With Stereotactic Radiosurgery (2012) (0)
- Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors (2019) (0)
- Correlation of shedding cryptic epitope (HU177) levels and treatment response in sera of melanoma patients (2008) (0)
- Abstract A194: PEGylated human IL-10 (AM0010) in advanced solid tumors (2015) (0)
- Multidisciplinary team management for high grade immune-related adverse events (irAEs): A single center experience. (2020) (0)
- Immune-checkpoint blockade in cancer immunotherapy (2014) (0)
- Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy. (2019) (0)
- Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma (2017) (0)
- Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma (2022) (0)
- Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma. (2021) (0)
- Resistance mechanisms to PD-1 inhibition in melanoma (2016) (0)
- Abstract 2846: Stereotypic patterns and genomic correlates of organotropism in metastatic melanoma (2021) (0)
- Abstract CT098: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors (2016) (0)
- Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases (2022) (0)
- ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS (2018) (0)
- Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy (2023) (0)
- What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR). (2018) (0)
- A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition. (2023) (0)
- Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma. (2010) (0)
- Highlights from the literature (2013) (0)
- Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
- PEGylated human IL-10 (AM0010) monotherapy in refractory metastatic colorectal cancer. (2017) (0)
- Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2017) (0)
- Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge (2017) (0)
- Abstract LB-147: Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study (2018) (0)
- Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas (2015) (0)
- Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy. (2023) (0)
- Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma. (2015) (0)
- 607 MCGRAW trial: evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients (2022) (0)
- 3PDPEGylated human IL-10 (AM0010) in advanced solid tumors (2015) (0)
- CLIN-MEDICAL + RADIATION THERAPIES (2012) (0)
- Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients. (2016) (0)
- Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy (2020) (0)
- Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect. (2021) (0)
- Contents Vol. 81, 2011 (2012) (0)
- Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma (2016) (0)
- Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS (2020) (0)
- [Results of combined treatment with intraoperative radial therapy of soft tissue sarcoma]. (2013) (0)
- Abstract A016: PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients (2019) (0)
- [Long-term results of combined treatment of soft tissue sarcoma with the use of intraoperative radiotherapy]. (2013) (0)
- 1 A cloning and expression system to probe T cell receptor specificity and assess functional avidity to neoantigens Running Head : Defining T cell receptor specificity to neoantigen (2018) (0)
- Abstract CT249: A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO) (2020) (0)
- Abstract A99: Management of advanced melanoma: improved survival and barriers to access in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies (2020) (0)
- Highlights from the literature (2019) (0)
- Promising Experimental Therapies for Metastatic Melanoma (2011) (0)
- Reply to F. Tomao et al. (2017) (0)
- Immunotherapy in Cancer (2019) (0)
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018) (0)
- Analyses of PD-L1 and In fl ammatory Gene Expression Association with Ef fi cacy of Nivolumab (cid:1) Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer (2021) (0)
- Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update. (2017) (0)
- Su1188 ABDOMINAL CT SHOULD NOT BE USED TO SCREEN FOR IMMUNE CHECKPOINT INHIBITOR COLITIS (2020) (0)
- Issue information (2013) (0)
- Cutaneous melanoma in the elderly: epidemiology and management (2010) (0)
- A first-in-human study of pegylated recombinant human IL-10 (AM0010), daily administered for four months in selected advanced solid tumors. (2014) (0)
- Treatment of Disseminated Melanoma (2011) (0)
- P0110 Safety and anti-tumour activity of pegylated recombinant human IL-10 (AM0010) in selected advanced solid tumours (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Patrick Alexander Ott?
Patrick Alexander Ott is affiliated with the following schools: